OMDA

Omada HealthA

Nasdaq / Health Care Equipment & Services

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$30.00

+25.6% vs current

Most likely

Base case

50%

Probability

Target price

$24.00

+0.5% vs current

B-

Bear case

25%

Probability

Target price

$16.00

-33.0% vs current

AI sentiment snapshot

Latest data as of 2026-07-08

AI commentary

Primary-source evidence is strong for the Q1 operating update, but external reaction breadth is thin in the packet. The only recent stored news item framed the quarter as a sales beat plus Lilly tie-up but noted the shares fell after the print, which tempers the otherwise positive filing-based setup. With no social coverage packet, no analyst revision set, and a loose peer group, sentiment is best treated as cautious-to-neutral with low buzz rather than a high-conviction momentum signal.

RankAlpha Sentiment Codex - 2026-07-08

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-06catalystQ1 beat and FY26 guidance raise need confirmationHigh impact

Omada reported Q1 revenue of $78 million, up 42% year over year, with gross margin up to 62%, adjusted EBITDA positive at $1 million, and FY26 revenue guidance raised to $322-$330 million from $312-$322 million; the next operating update is the key test of whether the post-IPO guide reset is durable rather than a one-quarter step-up [#SEC-8K-2026-05-07].

2026-12-31catalystOperating leverage and liquidity reduce near-term financing pressureHigh impact

Q1 net loss narrowed to $3 million from $9 million, adjusted EBITDA turned positive, and cash and cash equivalents were $212 million, supporting a thesis that Omada can fund growth while improving profitability if utilization and gross margin remain stable [#SEC-8K-2026-05-07].

2027-07-08catalystGLP-1 channel expansion could extend member and revenue growthHigh impact

Management said Omada now has relationships with all three leading PBMs and added Eli Lilly's Employer Connect as another employer channel for its GLP-1 Care Track and prescribing capabilities, which could expand employer adoption if conversion translates into sustained member adds and higher revenue per customer [#SEC-8K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-08 • Updated nightlySource: Internal modelMethodology